SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of CARGO Therapeutics, Inc. (Nasdaq – CRGX)
BALA CYNWYD – July 14, 2025/Globe Newswire/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of CARGO Therapeutics, Inc. (“CARGO” or the “Company”) (Nasdaq – CRGX) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Concentra Biosciences, LLC (“Concentra”). Under the terms of the transaction, Concentra will acquire CARGO for $4.379 in cash per share, plus one non-transferable contingent value right (“CVR”), which represents the right to receive: (i) 100% of the closing net cash of CARGO in excess of $217.5 million; and (ii) 80% of any net proceeds received within two years following closing from any disposition of certain of CARGO’s product candidates that occurs within two years following closing, each pursuant to a contingent value rights agreement.
If you own shares of CARGO stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman by email at clients@brodsky-smith.com, or call toll free 855-576-4847.
Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.